The potential role of statins in treating liver disease

References

• Stone NJ , Robinson JG , Lichtenstein AH , et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25Pt B):2889–2934.
   PubMed Web of Science ®Google Scholar
• Athyros VG , Katsiki N , Karagiannis A. Off target effects of statins shape total mortality? J Drug Assess. 2016;5(1):4–5.
   PubMed Web of Science ®Google Scholar
• Athyros VG , Kakafika AI , Tziomalos K , et al. Pleiotropic effects of statins–clinical evidence. Curr Pharm Des. 2009;15(5):479–489.
   PubMed Web of Science ®Google Scholar
• Tziomalos K , Athyros VG , Karagiannis A , et al. Lipid lowering agents and the endothelium: an update after 4 years. Curr Vasc Pharmacol. 2012;10(1):33–41.
   PubMed Web of Science ®Google Scholar
• Athyros VG , Tziomalos K , Karagiannis A , et al. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J. 2011;5:24–34.
   PubMedGoogle Scholar
• Parra JL , Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis. 2003;7:415–433.
   PubMedGoogle Scholar
• Tsochatzis EA , Bosch J , Burroughs AK. Future treatments of cirrhosis. Expert Rev Gastroenterol Hepatol. 2014;8(5):571–581.
   PubMed Web of Science ®Google Scholar
• Siegel A , El-Serag H . Statins for chemoprevention of hepatocellular carcinoma: assessing the evidence. Expert Rev Gastroenterol Hepatol. 2013;7(6):493–495.
   PubMed Web of Science ®Google Scholar
• Rafiq N , Younossi ZM . Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. Expert Rev Gastroenterol Hepatol. 2008;2(2):207–215.
   PubMedGoogle Scholar
• Lazaridis N , Tsochatzis E . Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Rev Gastroenterol Hepatol. 2017;11(4):357–369.
   PubMed Web of Science ®Google Scholar
• Hsu CS , Kao JH . An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia. Expert Rev Gastroenterol Hepatol. 2017;11(8):759–772.
   PubMed Web of Science ®Google Scholar
• Lonardo A , Ballestri S , Targher G , et al. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9(5):629–650.
   PubMed Web of Science ®Google Scholar
• Athyros VG , Katsiki N , Mikhailidis DP . Letter to the editor: treating nonalcoholic fatty liver disease with statins. Are all statins equal? Am J Physiol Gastrointest Liver Physiol. 2017;312(6):G681–G682.
   PubMed Web of Science ®Google Scholar
• Athyros VG , Boutari C , Stavropoulos K , et al. Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk. Curr Vasc Pharmacol. 2017 [Epub ahead of print]. DOI:10.2174/1570161115666170621082910
   Web of Science ®Google Scholar
• Athyros VG , Katsiki N , Mikhailidis DP . Statins and non-alcoholic steatohepatitis. Metabolism. 2017;66:e1–e2.
   PubMedGoogle Scholar
• Athyros VG , Katsiki N , Karagiannis A , et al. Statins and non-alcoholic steatohepatitis. J Hepatol. 2016;64(1):241–242.
   PubMed Web of Science ®Google Scholar
• Athyros VG , Tziomalos K , Katsiki N , et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. World J Gastroenterol. 2015;21(22):6820–6834.
   PubMed Web of Science ®Google Scholar
• Athyros VG , Katsiki N , Karagiannis A , et al. Statins and nonalcoholic fatty liver disease: a bright future? Expert Opin Investig Drugs. 2013;22(9):1089–1093.
   PubMed Web of Science ®Google Scholar
• Ji G , Zhao X , Leng L , et al. Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats. Lipids Health Dis. 2011;10:23–32.
   PubMed Web of Science ®Google Scholar
• Vilà L , Rebollo A , Ađalsteisson GS , et al. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment. Toxicol Appl Pharmacol. 2011;251(1):32–40.
   PubMed Web of Science ®Google Scholar
• Kabel AM , Elmaaboud MA , Albarraq AA . Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis. Prostaglandins Leukot Essent Fatty Acids. 2015;96:1–9.
   PubMed Web of Science ®Google Scholar
• Matafome P , Louro T , Rodrigues L , et al. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev. 2011;27(1):54–62.
   PubMed Web of Science ®Google Scholar
• El-Din SH , El-Lakkany NM , El-Naggar AA , et al. Effects of rosuvastatin and/or β-carotene on non-alcoholic fatty liver in rats. Res Pharm Sci. 2015;10(4):275–287.
   PubMed Web of Science ®Google Scholar
• Okada Y , Yamaguchi K , Nakajima T , et al. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats. Liver Int. 2013;33(2):301–311.
   PubMed Web of Science ®Google Scholar
• Chong LW , Hsu YC , Lee TF , et al. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. BMC Gastroenterol. 2015;15:22.
   PubMed Web of Science ®Google Scholar
• Miyaki T , Nojiri S , Shinkai N , et al. Pitavastatin inhibits hepatic steatosis and fibrosis in non-alcoholic steatohepatitis model rats. Hepatol Res. 2011;41(4):375–385.
   PubMed Web of Science ®Google Scholar
• Kiyici M , Gulten M , Gurel S , et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003;17:713–718.
   PubMed Web of Science ®Google Scholar
• Kimura Y , Hyogo H , Yamagishi S , et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol. 2010;45(7):750–757.
   PubMed Web of Science ®Google Scholar
• Athyros VG , Mikhailidis DP , Didangelos TP , et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006;22(5):873–883.
   PubMed Web of Science ®Google Scholar
• Athyros VG , Giouleme O , Ganotakis ES , et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci. 2011;7(5):796–805.
   PubMed Web of Science ®Google Scholar
• Nascimbeni F , Aron-Wisnewsky J , Pais R , et al. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016;3(1):e000075.
   PubMed Web of Science ®Google Scholar
• Ekstedt M , Franzén LE , Mathiesen UL , et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol. 2007;47(1):135–141.
   PubMed Web of Science ®Google Scholar
• Kargiotis K , Athyros VG , Giouleme O , et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol. 2015;21(25):7860–7868.
   PubMed Web of Science ®Google Scholar
• Bril F , Portillo Sanchez P , Lomonaco R , et al. Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial. J Clin Endocrinol Metab. 2017 Aug 1;102(8):2950–2961.
   PubMed Web of Science ®Google Scholar
• Rallidis LS , Drakoulis CK , Parasi AS . Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis. 2004;174(1):193–196.
   PubMed Web of Science ®Google Scholar
• Georgescu EF , Georgescu M . Therapeutic options in nonalcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis. 2007;16(1):39–46.
   PubMed Web of Science ®Google Scholar
• Hyogo H , Ikegami T , Tokushige K , et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open label, pilot study. Hepatol Res. 2011;41(11):1057–1065.
   PubMed Web of Science ®Google Scholar
• Nakahara T , Hyogo H , Kimura Y , et al. Efficacy of rosuvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res. 2012;42(11):1065–1072.
   PubMed Web of Science ®Google Scholar
• Athyros VG , Tziomalos K , Gossios TD , et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet. 2010;376(9756):1916–1922.
   PubMed Web of Science ®Google Scholar
• Tikkanen MJ , Fayyad R , Faergeman O , et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol. 2013;168(4):3846–3852.
   PubMed Web of Science ®Google Scholar
• Musso G , Cassader M , Rosina F , et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885–904.
   PubMed Web of Science ®Google Scholar
• Takeshita Y , Takamura T , Honda M , et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia. 2014;57:878–890.
   PubMed Web of Science ®Google Scholar
• Katsiki N , Mikhailidis DP , Mantzoros CS . Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65:1109–1123.
   PubMed Web of Science ®Google Scholar
• Capanni M , Calella F , Biagini MR , et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther. 2006;23:1143–1151.
   PubMed Web of Science ®Google Scholar
• Spadaro L , Magliocco O , Spampinato D , et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis. 2008;40:194–199.
   PubMedGoogle Scholar
• Nobili V , Alisi A , Della Corte C , et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis. 2013;23:1066–1070.
   PubMed Web of Science ®Google Scholar
• Argo CK , Patrie JT , Lackner C , et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol. 2015;62:190–197.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ , Abdelmalek MF , Suzuki A , et al. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014;147:377–384.
   PubMed Web of Science ®Google Scholar
• Tanaka N , Sano K , Horiuchi A , et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol. 2008;42:413–418.
   PubMed Web of Science ®Google Scholar
• Demers A , Samami S , Lauzier B , et al. PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler Thromb Vasc Biol. 2015;35:2517–2525.
   PubMed Web of Science ®Google Scholar
• Ruscica M , Ferri N , Macchi C , et al. Liver fat accumulation is associated with circulating PCSK9. Ann Med. 2016;48:384–391.
   PubMed Web of Science ®Google Scholar
• Hasegawa T , Yoneda M , Nakamura K , et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with nonalcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther. 2001;15:1667–1672.
   PubMed Web of Science ®Google Scholar
• Lavine JE , Schwimmer JB , Van Natta ML , et al. Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. Jama. 2011;305:1659–1668.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ , Chalasani N , Kowdley KV , et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ , Mofrad PS , Contos MJ , et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004;2:1107–1115.
   PubMed Web of Science ®Google Scholar
• Dufour JF , Oneta CM , Gonvers JJ , et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006;4:1537–1543.
   PubMed Web of Science ®Google Scholar
• Harrison SA , Torgerson S , Hayashi P , et al. Vitamin E and vitamin C treatment improves fibrosis is patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:2485–2490.
   PubMed Web of Science ®Google Scholar
• Del Ben M , Polimeni L , Baratta F , et al. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. Br J Clin Pharmacol. 2017 Jan;83(1):88–95.
   PubMed Web of Science ®Google Scholar
• Butt AA , Yan P , Bonilla H , et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES. Hepatology. 2015;62(2):365–374.
   PubMed Web of Science ®Google Scholar
• Simon TG , Bonilla H , Yan P , et al. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES. Hepatology. 2016;64(1):47–57.
   PubMed Web of Science ®Google Scholar
• Oliver NT , Hartman CM , Kramer JR , et al. Statin drugs decrease progression to cirrhosis in HIV/hepatitis C virus coinfected individuals. Aids. 2016;30(16):2469–2476.
   PubMed Web of Science ®Google Scholar
• Huang YW , Lee CL , Yang SS , et al. Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study. Am J Gastroenterol. 2016;111(7):976–985.
   PubMed Web of Science ®Google Scholar
• Wong JC , Chan HL , Tse YK , et al. Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. Aliment Pharmacol Ther. 2017;46(10):1001–1010.
   PubMed Web of Science ®Google Scholar
• Ma X , Sun D , Li C , et al. Statin use and virus-related cirrhosis: a systemic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(5):533–542.
   PubMed Web of Science ®Google Scholar
• Wang Y , Xiong J , Niu M , et al. Statins and the risk of cirrhosis in hepatitis B or C patients: a systematic review and dose-response meta-analysis of observational studies. Oncotarget. 2017;8(35):59666–59676.
   PubMedGoogle Scholar
• Trebicka J , Hennenberg M , Laleman W , et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology. 2007;46(1):242–253.
   PubMed Web of Science ®Google Scholar
• Abraldes JG , Rodríguez-Vilarrupla A , Graupera M , et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol. 2007;46(6):1040–1046.
   PubMed Web of Science ®Google Scholar
• Zafra C , Abraldes JG , Turnes J , et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004;126(3):749–755.
   PubMed Web of Science ®Google Scholar
• Chang FM , Wang YP , Lang HC , et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology. 2017;66(3):896–907.
   PubMed Web of Science ®Google Scholar
• Bang UC , Benfield T , Bendtsen F . Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study. Aliment Pharmacol Ther. 2017;46(7):673–680.
   PubMed Web of Science ®Google Scholar
• Abraldes JG , Albillos A , Bañares R , et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136(5):1651–1658.
   PubMed Web of Science ®Google Scholar
• Kim RG , Loomba R , Prokop LJ , et al. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521–1530.
   PubMed Web of Science ®Google Scholar
• Kamal S , Khan MA , Seth A , et al. Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis. Am J Gastroenterol. 2017;112(10):1495–1505.
   PubMed Web of Science ®Google Scholar
• Alkofer B , Lepennec V , Chiche L . Hepatocellular cancer in the non-cirrhotic liver. J Visc Surg. 2011;148(1):3–11.
   PubMed Web of Science ®Google Scholar
• Singh S , Singh PP , Roberts LR , et al. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2014;11(1):45–54.
   PubMed Web of Science ®Google Scholar
• Zhou YY , Zhu GQ , Wang Y , et al. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. Oncotarget. 2016;7(16):21753–21762.
   PubMed Web of Science ®Google Scholar
• Singh S , Singh PP , Singh AG , et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144(2):323–332.
   PubMed Web of Science ®Google Scholar
• Shi M , Zheng H , Nie B , et al. Statin use and risk of liver cancer: an update meta-analysis. BMJ Open. 2014;4(9):e005399.
   PubMed Web of Science ®Google Scholar
• Tsan YT , Lee CH , Wang JD , et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012;30(6):623–630.
   PubMed Web of Science ®Google Scholar
• Hsiang JC , Wong GL , Tse YK , et al. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity score landmark analysis. J Hepatol. 2015;63(5):1190–1197.
   PubMed Web of Science ®Google Scholar
• Chen CI , Kuan CF , Fang YA , et al. Cancer risk in HBV patients with statin and metformin use: a population-based cohort study. Medicine (Baltimore). 2015;94(6):e462.
   PubMed Web of Science ®Google Scholar
• Shao JY , Lee FP , Chang CL , et al. Statin-based palliative therapy for hepatocellular carcinoma. Medicine (Baltimore). 2015;94(42):e1801.
   PubMed Web of Science ®Google Scholar
• Llovet JM , Ricci S , Mazzaferro V , et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
   PubMed Web of Science ®Google Scholar
• Kawata S , Yamasaki E , Nagase T , et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer. 2001;84(7):886–891.
   PubMed Web of Science ®Google Scholar
• Graf H , Jüngst C , Straub G , et al. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion. 2008;78(1):34–38.
   PubMed Web of Science ®Google Scholar
• Goldstein JL , Brown MS . A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161:161–172.
   PubMed Web of Science ®Google Scholar
• Gruzdeva O , Uchasova E , Dyleva Y , et al. Early effects of treatment low-dose atorvastatin on markers of insulin resistance and inflammation in patients with myocardial infarction. Front Pharmacol. 2016;7:324.
   Web of Science ®Google Scholar
• Schierwagen R , Maybüchen L , Hittatiya K , et al. Statins improve NASH via inhibition of RhoA and Ras. Am J Physiol - Gastrointest Liver Physiol. 2016;311(4):G724-G733.
   PubMed Web of Science ®Google Scholar
• Hyogo H , Yamagishi S , Maeda S , et al. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property. Dig Liver Dis. 2012 Jun;44(6):492–496.
   PubMedGoogle Scholar
• Marrone G , Russo L , Rosado E , et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol. 2013;58:98–103.
   PubMed Web of Science ®Google Scholar
• Trebicka J , Hennenberg M , Odenthal M , et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol. 2010;53:702–712.
   PubMed Web of Science ®Google Scholar
• Relja B , Meder F , Wang M , et al. Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK. Int J Oncol. 2011;38:879–885.
   PubMed Web of Science ®Google Scholar
• Trebicka J , Hennenberg M , Laleman W , et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatol Baltim Md. 2007;46:242–253.
   PubMed Web of Science ®Google Scholar
• Bader T , Fazili J , Madhoun M , et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol. 2008;103:1383–1389.
   PubMed Web of Science ®Google Scholar
• Uschner FE , Ranabhat G , Choi SS , et al. Statins activate the canonical hedgehog-signaling and aggravate non cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Sci Rep. 2015;5:14573.
   PubMed Web of Science ®Google Scholar
• Runyon BA . Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651–1653.
   PubMed Web of Science ®Google Scholar
• Ghany MG , Nelson DR , Strader DB , et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433–1444.
   PubMed Web of Science ®Google Scholar
• O’Shea RS , Dasarathy S , McCullough AJ . Alcoholic liver disease. Hepatology. 2010;51(1):307–328.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver . EASL recommendations on treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153–194.
   PubMedGoogle Scholar
• European Association For The Study Of The Liver; European Organisation for Research and Treatment of Cancer . EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver . EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392–420.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver . EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–185.
   PubMed Web of Science ®Google Scholar
• AASLD/IDSA HCV Guidance Panel . Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–954.
   PubMed Web of Science ®Google Scholar
• Feld J , Janssen HL , Abbas Z , et al. World Gastroenterology Organisation global guideline hepatitis B: September 2015. J Clin Gastroenterol. 2016;50(9):691–703.
   PubMed Web of Science ®Google Scholar
• Umar M , Khan AG , Abbas Z , et al. World Gastroenterology Organisation global guidelines: diagnosis, management and prevention of hepatitis C April 2013. J Clin Gastroenterol. 2014;48(3):204–217.
   PubMed Web of Science ®Google Scholar
• Ferenci P , Fried M , Labrecque D , et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 2010;44(4):239–245.
   PubMed Web of Science ®Google Scholar
• Kanwal F , Bacon BR , Beste LA , et al. Hepatitis C virus infection care pathway-a report from the american gastroenterological association institute HCV Care Pathway Work Group. Gastroenterology. 2017;152(6):1588–1598.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of Liver . EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57(2):399–420.
   PubMed Web of Science ®Google Scholar
• Terrault NA , Bzowej NH , Chang KM , et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–283.
   PubMed Web of Science ®Google Scholar
• Heimbach JK , Kulik LM , Finn R , et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017 Epub ahead of print. DOI:10.1002/hep.29086
   Web of Science ®Google Scholar
• Riley P , Sudarshi D , Johal M , et al. Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study. Int J Clin Pract. 2008;62:374.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) . EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402.
   PubMed Web of Science ®Google Scholar
• Chalasani N , Younossi Z , Lavine JE , et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–1609.
   PubMed Web of Science ®Google Scholar
• Review Team, LaBrecque DR , Abbas Z , et al. World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol 2014;48(6):467–473.
   PubMed Web of Science ®Google Scholar
• Targher G , Day CP , Bonora E . Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–1350.
   PubMed Web of Science ®Google Scholar
• Del Ben M , Baratta F , Polimeni L , et al. Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2017;27(2):161–167.
   PubMed Web of Science ®Google Scholar
• Athyros VG , Alexandrides TK , Bilianou H , et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism. 2017;71:17–32.
   PubMed Web of Science ®Google Scholar
• Nelson A , Torres DM , Morgan AE , et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43(10):990–994.
   PubMed Web of Science ®Google Scholar
• Mitsiou E , Boutari C , Kotsis V , et al. Effect of low (5 mg) vs high (20-40 mg) rosuvastatin dose on 24h arterial stiffness, central haemodynamics, and non-alcoholic fatty liver disease in patients with optimally controlled arterial hypertension. Curr Vasc Pharmacol. 2017 [Epub ahead of print]. DOI:10.2174/1570161115666170630122833
   PubMed Web of Science ®Google Scholar
• Boutari C , Lefkos P , Athyros VG , et al. Nonalcoholic fatty liver disease vs. nonalcoholic steatohepatitis: pathological and clinical implications. Curr Vasc Pharmacol. 2017 [Epub ahead of print]. DOI:10.2174/1570161115666170621075157
   PubMed Web of Science ®Google Scholar